Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

Everolimus is currently approved in Europe as an adjunctive therapy for patients aged ≥ 2 years with tuberous sclerosis complex (TSC)–associated treatment‐refractory partial‐onset seizures, based on the EXIST‐3 study (NCT01713946) results. As TSC‐associated seizures can also affect children aged bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Combes, Francois Pierre, Einolf, Heidi J., Coello, Neva, Heimbach, Tycho, He, Handan, Grosch, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180003/
https://www.ncbi.nlm.nih.gov/pubmed/32150661
http://dx.doi.org/10.1002/psp4.12502

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180003/
https://www.ncbi.nlm.nih.gov/pubmed/32150661
http://dx.doi.org/10.1002/psp4.12502

Ejemplares similares